InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
InMed Pharmaceuticals (NASDAQ: INM) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York. The company's Chief Operating Officer, Michael Woudenberg, will deliver a corporate presentation highlighting updates on InMed's pipeline, including recent data from their leading pharmaceutical program INM-901 for Alzheimer's treatment.
The presentation will be available via webcast for 90 days, and InMed's management team will conduct one-on-one meetings with investors during the conference. The recent data from INM-901 was previously presented at the Alzheimer's Association International Conference (AAIC) 2025.
InMed Pharmaceuticals (NASDAQ: INM) ha annunciato la sua partecipazione al 27º H.C. Wainwright Annual Global Investment Conference a New York. Il Chief Operating Officer della società, Michael Woudenberg, terrà una presentazione aziendale con aggiornamenti sul portafoglio pipeline di InMed, inclusi i dati recenti dal principale programma farmaceutico INM-901 per il trattamento dell'Alzheimer.
La presentazione sarà disponibile in webcast per 90 giorni e il team dirigenziale di InMed terrà incontri one-to-one con gli investitori durante la conferenza. I dati recenti di INM-901 erano stati presentati in precedenza all'Alzheimer's Association International Conference (AAIC) 2025.
InMed Pharmaceuticals (NASDAQ: INM) anunció su participación en la 27.ª Conferencia Anual Global de Inversión de H.C. Wainwright en Nueva York. El Director de Operaciones de la compañía, Michael Woudenberg, ofrecerá una presentación corporativa con actualizaciones sobre la cartera de proyectos de InMed, incluyendo datos recientes de su principal programa farmacéutico INM-901 para el tratamiento del Alzheimer.
La presentación estará disponible en webcast durante 90 días y el equipo directivo de InMed realizará reuniones individuales con inversores durante la conferencia. Los datos recientes de INM-901 se presentaron anteriormente en la Alzheimer's Association International Conference (AAIC) 2025.
InMed Pharmaceuticals (NASDAQ: INM)는 뉴욕에서 열리는 제27회 H.C. Wainwright 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 회사의 최고운영책임자(COO) Michael Woudenberg가 기업 프레젠테이션을 통해 알츠하이머 치료를 위한 주력 의약 프로그램 INM-901을 포함한 InMed 파이프라인의 최신 내용을 발표할 예정입니다.
프레젠테이션은 90일간 웹캐스트로 제공되며, InMed 경영진은 컨퍼런스 기간 동안 투자자들과 일대일 미팅을 진행합니다. INM-901의 최근 데이터는 이전에 Alzheimer's Association International Conference (AAIC) 2025에서 발표된 바 있습니다.
InMed Pharmaceuticals (NASDAQ: INM) a annoncé sa participation à la 27e conférence annuelle mondiale des investisseurs H.C. Wainwright à New York. Le directeur des opérations de la société, Michael Woudenberg, présentera une conférence d'entreprise avec des mises à jour sur le pipeline d'InMed, y compris les données récentes de leur principal programme pharmaceutique INM-901 pour le traitement de la maladie d'Alzheimer.
La présentation sera disponible en webcast pendant 90 jours et l'équipe de direction d'InMed tiendra des réunions individuelles avec des investisseurs pendant la conférence. Les données récentes d'INM-901 ont été présentées précédemment lors de la Alzheimer's Association International Conference (AAIC) 2025.
InMed Pharmaceuticals (NASDAQ: INM) gab bekannt, dass das Unternehmen an der 27. H.C. Wainwright Annual Global Investment Conference in New York teilnimmt. Der Chief Operating Officer, Michael Woudenberg, wird eine Unternehmenspräsentation halten und Updates zur Pipeline von InMed vorstellen, darunter aktuelle Daten zu dem führenden Pharmaprogramm INM-901 zur Behandlung von Alzheimer.
Die Präsentation wird für 90 Tage per Webcast verfügbar sein, und das Managementteam von InMed wird während der Konferenz Einzelgespräche mit Investoren führen. Die jüngsten Daten zu INM-901 wurden bereits auf der Alzheimer's Association International Conference (AAIC) 2025 vorgestellt.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of InMed's management team will also be conducting one-on-one meetings with investors. Additionally a corporate presentation from the Company will be available online.
In the presentation, Mr. Michael Woudenberg, InMed's Chief Operating Officer, will highlight updates and progress of InMed's pipeline including recent data from the Company's leading pharmaceutical program INM-901 in the treatment of Alzheimer's, that was recently presented at Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease and dementia research.
H.C. Wainwright 27th Annual Global Investment Conference
Presentation Link: https://journey.ct.events/view/09f2e465-e7f2-45b7-83d6-e1fb4303ebc4
The webcast will be available for 90 days at the link above or on the InMed Investor Relations Events page: https://www.inmedpharma.com/investors/events/
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: a corporate presentation highlighting recent updates and progress with InMed's pipeline including recent data from the Company's lead program INM-901 in the treatment of Alzheimer's
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265322
FAQ
When is InMed Pharmaceuticals (INM) presenting at the H.C. Wainwright Conference 2025?
What will be discussed in InMed's (INM) presentation at the H.C. Wainwright Conference?
How can investors access InMed's (INM) H.C. Wainwright Conference presentation?
What is InMed Pharmaceuticals' (INM) main drug candidate for Alzheimer's?
